Swaroop Kumar Pandey

Dr. Swaroop Kumar Pandey

Biotechnology, GLA University, Mathura, India
orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2021 in Drug Resistance Updates
Verified
Journal Article
Closed access
TDTuyelee Das
Tuyelee Das
UAUttpal Anand
Uttpal Anand
Swaroop Kumar PandeySwaroop Kumar Pandey
Swaroop Kumar Pandey
CACharles R. Ashby
Charles R. Ashby
YAYehuda G. Assaraf
Yehuda G. Assaraf
ADAbhijit Dey
Abhijit Dey

1 January 2009 in Bioorganic & Medicinal Chemistry
Verified
Journal Article
Closed access
MMMridul Misra
Mridul Misra
Swaroop Kumar PandeySwaroop Kumar Pandey
Swaroop Kumar Pandey
VPVivek Parashar Pandey
Vivek Parashar Pandey
JPJyoti Pandey
Jyoti Pandey
RTRenu Tripathi
Renu Tripathi
RTRama Pati Tripathi
Rama Pati Tripathi

28 December 2022 in Translational Neurodegeneration
Verified
Journal Article
Open access
PDF file
AVAnkit Verma
Ankit Verma
ASAnna Shteinfer-Kuzmine
Anna Shteinfer-Kuzmine
NKNikita Kamenetsky
Nikita Kamenetsky
SPSrinivas Pittala
Srinivas Pittala
APAvijit Paul
Avijit Paul
Varda Shoshan-BarmatzVarda Shoshan-Barmatz
Varda Shoshan-Barmatz
Background: Alzheimer's disease (AD) exhibits mitochondrial dysfunctions associated with dysregulated metabolism, brain inflammation, synaptic loss, and neuronal cell death. As a key protein serving as the mitochondrial gatekeeper, the voltage-dependent anion channel-1 (VDAC1) that controls metabolism and Ca2+homeostasis is positioned at a convergence point for various cell survival and death signals. Here, we targeted VDAC1 with VBIT-4, a newly developed inhibitor of VDAC1 that prevents its pro-apoptotic activity, and mitochondria dysfunction.Methods: To address the multiple pathways involved in AD, neuronal cultures and a 5 × FAD mouse model of AD were treated with VBIT-4. We addressed multiple topics related to the disease and its molecular mechanisms using immunoblotting, immunofluorescence, q-RT-PCR, 3-D structural analysis and several behavioral tests.Results: In neuronal cultures, amyloid-beta (Aβ)-induced VDAC1 and p53 overexpression and apoptotic cell death were prevented by VBIT-4. Using an AD-like 5 × FAD mouse model, we showed that VDAC1 was overexpressed in neurons surrounding Aβ plaques, but not in astrocytes and microglia, and this was associated with neuronal cell death. VBIT-4 prevented the associated pathophysiological changes including neuronal cell death, neuroinflammation, and neuro-metabolic dysfunctions. VBIT-4 also switched astrocytes and microglia from being pro-inflammatory/neurotoxic to neuroprotective phenotype. Moreover, VBIT-4 prevented cognitive decline in the 5 × FAD mice as evaluated using several behavioral assessments of cognitive function. Interestingly, VBIT-4 protected against AD pathology, with no significant change in phosphorylated Tau and only a slight decrease in Aβ-plaque load.Conclusions: The study suggests that mitochondrial dysfunction with its gatekeeper VDAC1 is a promising target for AD therapeutic intervention, and VBIT-4 is a promising drug candidate for AD treatment.

1 January 2009 in Bioorganic & Medicinal Chemistry
Verified
Journal Article
Closed access
SMS. Madapa
S. Madapa
ZTZ. Tusi
Z. Tusi
AMA. Mishra
A. Mishra
KSK. Srivastava
K. Srivastava
Swaroop Kumar PandeySwaroop Kumar Pandey
Swaroop Kumar Pandey
SBS. Batra
S. Batra

1 April 2017 in Neoplasia
Verified
Journal Article
Open access
JNJessica J. Nunes
Jessica J. Nunes
Swaroop Kumar PandeySwaroop Kumar Pandey
Swaroop Kumar Pandey
AYAnjali Yadav
Anjali Yadav
SGSakshi Goel
Sakshi Goel
BABushra Ateeq
Bushra Ateeq
Androgen deprivation therapy (ADT) is the most preferred treatment for men with metastatic prostate cancer (PCa). However, the disease eventually progresses and develops resistance to ADT in majority of the patients, leading to the emergence of metastatic castration-resistant prostate cancer (mCRPC). Here, we assessed artesunate (AS), an artemisinin derivative, for its anticancer properties and ability to alleviate resistance to androgen receptor (AR) antagonists. We have shown AS in combination with bicalutamide (Bic) attenuates the oncogenic properties of the castrate-resistant (PC3, 22RV1) and androgen-responsive (LNCaP) PCa cells. Mechanistically, AS and Bic combination inhibits nuclear factor (NF)-κB signaling and decreases AR and/or AR-variant 7 expression via ubiquitin-mediated proteasomal degradation. The combination induces oxidative stress and apoptosis via survivin downregulation and caspase-3 activation, resulting in poly-ADP-ribose polymerase (PARP) cleavage. Moreover, preclinical castrate-resistant PC3 xenograft studies in NOD/SCID mice (n =28, seven per group) show remarkable tumor regression and significant reduction in lungs and bone metastases upon administering AS (50 mg/kg per day in two divided doses) and Bic (50 mg/kg per day) via oral gavage. Taken together, we for the first time provide a compelling preclinical rationale that AS could disrupt AR antagonist-mediated resistance observed in mCRPC. The current study also indicates that the therapeutic combination of Food and Drug Administration-approved AS or NF-κB inhibitors and AR antagonists may enhance the clinical efficacy in the treatment of mCRPC patients.

1 September 2012 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
SFSeerat Fatima
Seerat Fatima
ASAnindra Sharma
Anindra Sharma
RSReshu Saxena
Reshu Saxena
RTRajkamal Tripathi
Rajkamal Tripathi
SSSanjeev K. Shukla
Sanjeev K. Shukla
RTRama P. Tripathi
Rama P. Tripathi